Sensus Healthcare, Inc. (NASDAQ:SRTS) Shares Bought by Marshall Wace LLP

Marshall Wace LLP raised its stake in Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) by 99.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 132,286 shares of the company's stock after buying an additional 65,994 shares during the quarter. Marshall Wace LLP owned about 0.81% of Sensus Healthcare worth $915,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. Arrowstreet Capital Limited Partnership boosted its position in shares of Sensus Healthcare by 81.2% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company's stock worth $1,039,000 after purchasing an additional 67,269 shares during the period. O Shaughnessy Asset Management LLC increased its stake in Sensus Healthcare by 65.1% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 93,248 shares of the company's stock worth $645,000 after buying an additional 36,785 shares during the period. Integrated Quantitative Investments LLC acquired a new position in shares of Sensus Healthcare in the fourth quarter worth $251,000. Sigma Planning Corp acquired a new position in Sensus Healthcare during the 4th quarter worth $215,000. Finally, Virtu Financial LLC acquired a new stake in Sensus Healthcare in the 4th quarter valued at about $189,000. Hedge funds and other institutional investors own 25.30% of the company's stock.

Sensus Healthcare Stock Up 1.0 %

SRTS traded up $0.04 on Tuesday, reaching $4.11. The company had a trading volume of 13,858 shares, compared to its average volume of 247,807. The stock has a 50-day moving average price of $4.62 and a 200-day moving average price of $6.25. The stock has a market capitalization of $67.79 million, a PE ratio of 10.28 and a beta of 1.30. Sensus Healthcare, Inc. has a 1 year low of $3.68 and a 1 year high of $9.33.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.09 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. As a group, analysts expect that Sensus Healthcare, Inc. will post 0.32 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Lake Street Capital lowered their price target on shares of Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. HC Wainwright restated a "buy" rating and issued a $12.00 price target on shares of Sensus Healthcare in a research note on Friday, April 4th.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.